Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dolutegravir/lamivudine - GSK

Next Previous
Drug Profile

Dolutegravir/lamivudine - GSK

Alternative Names: Dovato; DTG/3TC; Lamivudine/dolutegravir

Latest Information Update: 06 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK; ViiV Healthcare
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Deoxyribonucleosides; Dideoxynucleosides; Oxazines; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action HIV integrase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 18 Sep 2025 Phase-III clinical trials in HIV-1 infections (Treatment-naive) in Brazil (PO) (NCT06497465)
  • 08 Apr 2024 Registration for HIV-1 infections (In adolescents, Treatment-naive, In adults, In the elderly) in USA (PO)
  • 09 Feb 2024 Phase-III clinical trials in HIV-1 infections (Treatment-naive) in United Kingdom, Switzerland, Sweden, Spain, Portugal, Poland, Mexico, Japan, Italy, Israel, Ireland, Greece, Germany, France, Denmark, Belgium, Argentina (PO) (NCT05979311)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top